ule 2.7, 3.10.3, 3.10.4, 3.10.5

### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/oo, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12, \ o4/o3/13$ 

ABN		
2 000	817 023	
We (t	he entity) give ASX the following	g information.
	1 - All issues ust complete the relevant sections (attac	h sheets if there is not enough space).
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	Ordinary Shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	7,058,754
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Ordinary Shares

Name of entity
TNG Limited

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes
5	Issue price or consideration	\$0.08
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Exercise of Listed Options
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	27/11/2014
6c	Number of *securities issued without security holder approval under rule 7.1	Nil

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6d	Number of *securities issued	Nil	
	with security holder approval under rule 7.1A		
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of *securities issued under an exception in rule 7.2	7,058,754 Ordinary Share	es
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	See Annexure 1 attached.	
7	*Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	24/7/2015	
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	Number 679,677,145 33,491,572	+Class Ordinary Shares Options exercisable at \$0.08 expiring on 31 July 2015

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (including the \*securities in section 2 if applicable)

Number	+Class
1,600,000	Unlisted Options – exercise price \$0.235, expiry 26 November 2015
4,000,000	Unlisted Options – exercise price \$0.057, expiry 26 November 2016
4,500,000	Unlisted Options – exercise price \$0.15, expiry 6 June 2017
1,000,000	Unlisted Options – exercise price \$0.15, expiry 4 January 2017

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

No Policy		

### Part 2 - Pro rata issue

11	Is security holder approval required?	Part 2 not applicable.
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	
15	<sup>+</sup> Record date to determine entitlements	

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on	
25	If the issue is contingent on security holders' approval, the date of the meeting	
_	Determination of the control of the	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	

<sup>+</sup> See chapter 19 for defined terms.

27	and holde exerc	ise, the date on which es will be sent to option	
28	Date applic	rights trading will begin (if cable)	
29	Date applic	rights trading will end (if cable)	
30		do security holders sell entitlements <i>in full</i> through ker?	
31			
32	of the	do security holders dispose eir entitlements (except by hrough a broker)?	
33	<sup>+</sup> Issue	e date	
	ed only o	of <sup>+</sup> securities	<b>S</b> oplying for quotation of securities
(a)		<sup>+</sup> Securities described in Part	1
(b)		•	nd of the escrowed period, partly paid securities that become fully paid en restriction ends, securities issued on expiry or conversion of convertible
Entiti	es tha	t have ticked box 34(a)	
Addi	tional	securities forming a nev	v class of securities

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Tick to docume	indicate you are providing the information or ents
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additiona *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional *securities
Entiti	es that have ticked box 34(b)
38	Number of *securities for which *quotation is sought
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

<sup>+</sup> See chapter 19 for defined terms.

41	Reason for request for quotation now	
	Example: In the case of restricted securities, end of restriction period	
	(if issued upon conversion of another *security, clearly identify that other *security)	

42 Number and \*class of all \*securities quoted on ASX (including the \*securities in clause 38)

Number	+Class

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

• Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

		24/7/2015
Sign here:		Date:
	(Company secretary)	

11 Robertson

Print name: Simon Robertson

== == == ==

<sup>+</sup> See chapter 19 for defined terms.

### Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital  Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Add the following:		
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period under an exception in rule 7.2	27/11/2014 12,000,000 (Exception 9) 05/01/2015 1,500 000 (Exception 9) Various 27,925,161 (Exception 4)	
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval	31/10/2014 51,483,325 (meeting 20/05/2015) 31/10/2014 3,116,680 (meeting 20/05/2015) 4/11/2014 400,000 (meeting 20/05/2015)	
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period		
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	-	
"A"	650,523,812	

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15	97,578,572	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
<ul> <li>Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:</li> <li>Under an exception in rule 7.2</li> <li>Under rule 7.1A</li> </ul>	4/11/2014 319,833 Listed Options 5/1/2015 100,000 Ordinary Shares 24/4/2015 15,720,000 Ordinary Shares 26/5/2015 13,333,333 Ordinary Shares	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	29,473,166	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	97,578,572	
Note: number must be same as shown in Step 2		
Subtract "C"	29,473,166	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	68,105,406	
	[Note: this is the remaining placement capacity under rule 7.1]	

### Part 2

<sup>+</sup> See chapter 19 for defined terms.

Rule 7.1A – Additional placement capacity for eligible entities  Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Step 2: Calculate 10% of "A"		
0.10		
Note: this value cannot be changed		
65,052,381		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
-		
_		

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	65,052,381	
Note: number must be same as shown in Step 2		
Subtract "E"	-	
Note: number must be same as shown in		

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B Page 12 04/03/2013

Step 3	
<i>Total</i> ["A" x 0.10] – "E"	65,052,381
	Note: this is the remaining placement capacity under rule 7.1A

<sup>+</sup> See chapter 19 for defined terms.